EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Preoperative Avapritinib for Localized PDGFRA ‐Mutant GIST : Marked Pathologic Response, but Limited Feasibility at Standard Dosing

Tannaz Ranjbarian iD, Mark Antkowiak, Shirley Sarno, Shumei Kato, Adam M Burgoyne, Skye C Mayo, Michael C Heinrich, Paul T Fanta, Jason K Sicklick iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72100 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Tannaz Ranjbarian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: Avapritinib, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors, Protein Kinase Inhibitors. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Veterans Affairs VA Merit Review Grant, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Avapritinib is a selective tyrosine kinase inhibitor approved for advanced PDGFRA exon 18–mutant gastrointestinal stromal tumors (GIST), including the imatinib‐resistant D842V variant. However, its role in the preoperative setting for localized, resectable disease has not been defined.

Methods

We conducted a retrospective two‐center exploratory case series of eight patients with localized, resectable PDGFRA ‐mutant gastric GIST who received preoperative avapritinib between 2020 and 2025. Radiographic and pathologic responses, treatment duration, adverse events (AEs), and surgical outcomes were evaluated.

Results

All patients initiated avapritinib at 300 mg daily. Median treatment duration was 2 months (range, < 1–21 months). Tumor size decreased in seven patients (88%), with a median reduction of 25% and an overall range from −51% to +29%. Three patients (38%) met RECIST‐based thresholds for partial response (≥ 30% reduction). Five patients underwent surgical resection, all achieving complete (0% viable tumor) or near‐complete (≤ 5% viable tumor) pathologic response. Dose reductions were required in three patients due to toxicity; however, tumor regression continued in all. Treatment‐related grade ≥ 3 AEs occurred in 50% of patients, including one fatal intracranial hemorrhage. Most toxicities emerged within two months, and most nonfatal toxicities improved with dose adjustment or discontinuation.

Conclusions

In this exploratory two‐center case series, preoperative avapritinib demonstrated marked pathologic activity in localized PDGFRA ‐mutant GIST, including after dose reduction in some patients. However, early toxicity at the standard 300 mg dose was frequent and, in several cases, prevented patients from reaching planned surgery. These findings argue against routine preoperative avapritinib use and support limiting this approach to clinical trials or highly selected patients with a compelling surgical rationale until prospective data are available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AvapritinibGastrointestinal NeoplasmsGastrointestinal Stromal TumorsProtein Kinase InhibitorsPyrazolesPyrrolesReceptor, Platelet-Derived Growth Factor alphaAdultAgedFemaleHumansMaleMiddle AgedFeasibility StudiesMutationRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

platelet derived growth factor receptor aGISTpathologic responseradiologic responsetargeted therapytreatment‐related toxicity

Substanzen

AvapritinibProtein Kinase InhibitorsPyrazolesPyrrolesReceptor, Platelet-Derived Growth Factor alpha

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, California, USA.
  • Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
  • Division of Hematology-Oncology, Department of Medicine, University of California San Diego, San Diego, California, USA.
  • Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University (OHSU), Portland, Oregon, USA.
  • OHSU Knight Cancer Institute, Portland, Oregon, USA.
  • Portland VA Health Care System, Portland, Oregon, USA.

ORCID-Profile: Tannaz Ranjbarian, Jason K Sicklick

Förderung

  • U.S. Department of Veterans Affairs VA Merit Review Grant
  • NIH HHS
  • NCI NIH HHS
  • GIST Support International
  • GIST Cancer Research Fund
  • BLRD VA
  • Jon Strong
  • National Institutes of Health

Zitieren

APA

Ranjbarian, T., Antkowiak, M., Sarno, S., Kato, S., Burgoyne, A. M., Mayo, S. C., Heinrich, M. C., Fanta, P. T., & Sicklick, J. K. (2026). Preoperative Avapritinib for Localized PDGFRA ‐Mutant GIST : Marked Pathologic Response, but Limited Feasibility at Standard Dosing. Cancer Medicine. https://doi.org/10.1002/cam4.72100

Vancouver

Ranjbarian T, Antkowiak M, Sarno S, Kato S, Burgoyne AM, Mayo SC, et al. Preoperative Avapritinib for Localized PDGFRA ‐Mutant GIST : Marked Pathologic Response, but Limited Feasibility at Standard Dosing. Cancer Medicine. 2026. doi:10.1002/cam4.72100

BibTeX
@article{Ranjbarian2026,
  author = {Ranjbarian, Tannaz and Antkowiak, Mark and Sarno, Shirley and Kato, Shumei and Burgoyne, Adam M and Mayo, Skye C and Heinrich, Michael C and Fanta, Paul T and Sicklick, Jason K},
  title = {Preoperative Avapritinib for Localized PDGFRA ‐Mutant GIST : Marked Pathologic Response, but Limited Feasibility at Standard Dosing},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72100}
}
Kostenlos starten →